CANbridge, Azaya enter agreement

Friday, September 27, 2013

CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has partnered with Azaya Therapeutics in San Antonio, Texas, to develop and commercialize Azaya’s investigational drug, ATI-1123, for treatment of non-small cell lung cancer (NSCLC), and potentially other solid tumor cancer indications, in China, Taiwan and South Korea.

[Read More]